405 related articles for article (PubMed ID: 30608114)
21. Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.
Ramli R; Reddy M; Oliver N
Drugs; 2019 Jul; 79(10):1089-1101. PubMed ID: 31190305
[TBL] [Abstract][Full Text] [Related]
22. Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives.
Pathak V; Pathak NM; O'Neill CL; Guduric-Fuchs J; Medina RJ
Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419844521. PubMed ID: 31105434
[TBL] [Abstract][Full Text] [Related]
23. Management of type 1 diabetes.
De Beaufort C; Besançon S; Balde N
Med Sante Trop; 2018 Nov; 28(4):359-362. PubMed ID: 30799818
[TBL] [Abstract][Full Text] [Related]
24. The heterogeneous pathogenesis of type 1 diabetes mellitus.
Ilonen J; Lempainen J; Veijola R
Nat Rev Endocrinol; 2019 Nov; 15(11):635-650. PubMed ID: 31534209
[TBL] [Abstract][Full Text] [Related]
25. Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives.
Nishimura A; Matsumura K; Kikuno S; Nagasawa K; Okubo M; Mori Y; Kobayashi T
Diabetes Metab Syndr Obes; 2019; 12():2461-2477. PubMed ID: 31819572
[TBL] [Abstract][Full Text] [Related]
26. T-Cell Epitopes and Neo-epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal.
James EA; Mallone R; Kent SC; DiLorenzo TP
Diabetes; 2020 Jul; 69(7):1311-1335. PubMed ID: 32561620
[TBL] [Abstract][Full Text] [Related]
27. Assessing effector T cells in type 1 diabetes.
Arif S; Pujol-Autonell I; Eichmann M
Curr Opin Endocrinol Diabetes Obes; 2020 Aug; 27(4):240-247. PubMed ID: 32618636
[TBL] [Abstract][Full Text] [Related]
28. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.
Wiedeman AE; Muir VS; Rosasco MG; DeBerg HA; Presnell S; Haas B; Dufort MJ; Speake C; Greenbaum CJ; Serti E; Nepom GT; Blahnik G; Kus AM; James EA; Linsley PS; Long SA
J Clin Invest; 2020 Jan; 130(1):480-490. PubMed ID: 31815738
[TBL] [Abstract][Full Text] [Related]
29. Historical and new insights into pathogenesis of type 1 diabetes.
Wong FS; Tree TI
Clin Exp Immunol; 2019 Dec; 198(3):292-293. PubMed ID: 31729755
[TBL] [Abstract][Full Text] [Related]
30. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic treatment options for type 1 diabetes: what's new?
Nally LM; Sherr JL; Van Name MA; Patel AD; Tamborlane WV
Expert Rev Clin Pharmacol; 2019 May; 12(5):471-479. PubMed ID: 30892094
[TBL] [Abstract][Full Text] [Related]
32. Beta cells in type 1 diabetes: mass and function; sleeping or dead?
Oram RA; Sims EK; Evans-Molina C
Diabetologia; 2019 Apr; 62(4):567-577. PubMed ID: 30767048
[TBL] [Abstract][Full Text] [Related]
33. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).
Roep BO; Thomaidou S; van Tienhoven R; Zaldumbide A
Nat Rev Endocrinol; 2021 Mar; 17(3):150-161. PubMed ID: 33293704
[TBL] [Abstract][Full Text] [Related]
34. The Challenges to Advancing Induced Pluripotent Stem Cell-Dependent Cell Replacement Therapy.
Moy AB; Kamath A; Ternes S; Kamath J
Med Res Arch; 2023 Nov; 11(11):. PubMed ID: 38188933
[TBL] [Abstract][Full Text] [Related]
35. Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats.
Cristelo C; Nunes R; Pinto S; Marques JM; Gama FM; Sarmento B
ACS Pharmacol Transl Sci; 2023 Oct; 6(10):1544-1560. PubMed ID: 37854630
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of quality of life and depression in family caregivers of patients with type 1 diabetes in Iran: A case-control study.
Ghorbani R; Foroutan M; Kassaeian SS; Sadat Kia N; Gholizade Bajandi B; Haji Ghanbari A; Ghods E
SAGE Open Med; 2023; 11():20503121221146055. PubMed ID: 36643205
[TBL] [Abstract][Full Text] [Related]
37. Cu-Catalyzed Chan-Evans-Lam Coupling Reactions of 2-Nitroimidazole with Aryl Boronic Acids: An Effort toward New Bioactive Agents against S. pneumoniae.
Raju S; Sheridan PE; Hauer AK; Garrett AE; McConnell DE; Thornton JA; Stokes SL; Emerson JP
Chem Biodivers; 2022 Aug; 19(8):e202200327. PubMed ID: 35819995
[TBL] [Abstract][Full Text] [Related]
38. Quality of care in patients with type 1 diabetes during the COVID-19 pandemic: a cohort study from Southern Brazil.
Foppa L; Alessi J; Nemetz B; de Matos R; Telo GH; Schaan BD
Diabetol Metab Syndr; 2022 May; 14(1):75. PubMed ID: 35598019
[TBL] [Abstract][Full Text] [Related]
39. Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes.
Ríos-Ríos WJ; Sosa-Luis SA; Torres-Aguilar H
World J Diabetes; 2021 May; 12(5):603-615. PubMed ID: 33995848
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome Analysis Reveals Possible Immunomodulatory Activity Mechanism of
Wu S; Liu H; Li S; Sun H; He X; Huang Y; Long H
Mar Drugs; 2021 Apr; 19(4):. PubMed ID: 33919822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
